Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428695 | 0.94 | DPP4 (0.39) | DPP4CNR1RAB9A | |
| SCHEMBL28209789 | 0.94 | DPP4 (0.39) | DPP4CNR1RAB9A | |
| SCHEMBL23795131 | 0.85 | — | — | |
| SCHEMBL11478670 | 0.84 | CHRM2 (0.42) | GAAHPGDCHRM2CHRM4CHRM5 | |
| SCHEMBL11556836 | 0.82 | CHRM2 (0.44) | GAAHPGDCHRM2CHRM4CHRM5 | |
| SCHEMBL25187343 | 0.82 | GAA (0.36) | GAAHPGDDPP4FKBP1ACNR1 | |
| SCHEMBL11491026 | 0.82 | TSHR (0.44) | GAAHPGDFKBP1A | |
| SCHEMBL2727733 | 0.79 | HPGD (0.34) | GAAHPGDFKBP1ACHRM2CHRM4 | |
| SCHEMBL28890612 | 0.79 | HPGD (0.37) | GAAHPGDFKBP1ARAB9A | |
| SCHEMBL7110058 | 0.79 | RAB9A (0.36) | GAAHPGDDPP4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877390-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-109988186-A | Beta-lactamase inhibitor | 维纳拓尔斯制药公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-106687465-B | β -lactamase inhibitor | 维纳拓尔斯制药公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-106687465-A | Beta-lactamase inhibitors | 维纳拓尔斯制药公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-101896481-B | Pyrimidyl indoline compound | DAIICHI SANKYO CO LTD | 2014-04-30 | — | — | CN | disclosed |
| US-20130150366-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA, INTELLECTUAL PROPERTY (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| CN-101896481-A | Pyrimidyl indoline compound | DAIICHI SANKYO CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101801957-A | Pyridone GPR 119 g protein-coupled receptor agonists | BRISTOL MYERS SQUIBB CO | 2010-08-11 | — | — | CN | disclosed |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1000029-A1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002496-A1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150366-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, CFTR | GAA 154/4885HPGD 429/4885DPP4 2219/4885 |
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | GAA 4035/4885HPGD 1000/4885DPP4 3606/4885 |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | PIR, HAMP, AMPD2 | GAA 445/4885HPGD 760/4885DPP4 227/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | GAA 494/4885HPGD 394/4885DPP4 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.